Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bacterial Toxins | 6 | 2021 | 265 | 2.840 |
Why?
|
| Toxin-Antitoxin Systems | 4 | 2021 | 4 | 2.770 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 9 | 2020 | 29 | 2.460 |
Why?
|
| Bacterial Proteins | 5 | 2021 | 474 | 1.610 |
Why?
|
| Anti-Bacterial Agents | 10 | 2018 | 498 | 1.500 |
Why?
|
| Enzyme Inhibitors | 3 | 2020 | 247 | 1.370 |
Why?
|
| Escherichia coli Proteins | 2 | 2021 | 113 | 1.360 |
Why?
|
| Pseudomonas aeruginosa | 2 | 2021 | 62 | 1.320 |
Why?
|
| Protease La | 2 | 2021 | 4 | 1.310 |
Why?
|
| Folic Acid Antagonists | 6 | 2014 | 17 | 1.290 |
Why?
|
| Antitoxins | 2 | 2021 | 13 | 1.250 |
Why?
|
| Staphylococcus aureus | 5 | 2020 | 115 | 1.190 |
Why?
|
| Bacillus anthracis | 8 | 2015 | 146 | 1.170 |
Why?
|
| Bacteria | 4 | 2020 | 265 | 1.130 |
Why?
|
| Pyrimidines | 8 | 2015 | 121 | 1.100 |
Why?
|
| Drug Design | 2 | 2020 | 62 | 1.060 |
Why?
|
| Capsid | 5 | 2009 | 12 | 1.030 |
Why?
|
| Virus Assembly | 5 | 2009 | 9 | 1.020 |
Why?
|
| Hepatitis B virus | 5 | 2009 | 16 | 1.020 |
Why?
|
| Escherichia coli | 4 | 2021 | 329 | 0.930 |
Why?
|
| Phenotype | 2 | 2019 | 667 | 0.880 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2020 | 135 | 0.800 |
Why?
|
| Agrobacterium tumefaciens | 1 | 2021 | 5 | 0.730 |
Why?
|
| DNA Topoisomerase IV | 1 | 2019 | 4 | 0.660 |
Why?
|
| Proteobacteria | 1 | 2019 | 20 | 0.650 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2018 | 5 | 0.630 |
Why?
|
| Antiviral Agents | 3 | 2009 | 111 | 0.610 |
Why?
|
| Models, Molecular | 14 | 2021 | 445 | 0.580 |
Why?
|
| Gene Expression | 1 | 2019 | 407 | 0.570 |
Why?
|
| Phthalazines | 2 | 2015 | 22 | 0.560 |
Why?
|
| Endopeptidase Clp | 1 | 2016 | 9 | 0.530 |
Why?
|
| Molecular Docking Simulation | 2 | 2014 | 47 | 0.520 |
Why?
|
| Trimethoprim | 2 | 2020 | 6 | 0.500 |
Why?
|
| Structure-Activity Relationship | 5 | 2020 | 207 | 0.480 |
Why?
|
| Coenzymes | 1 | 2014 | 9 | 0.450 |
Why?
|
| Enterococcus faecalis | 1 | 2014 | 71 | 0.430 |
Why?
|
| Crystallography, X-Ray | 6 | 2021 | 218 | 0.400 |
Why?
|
| Signal Transduction | 1 | 2016 | 1374 | 0.340 |
Why?
|
| Binding Sites | 5 | 2020 | 342 | 0.340 |
Why?
|
| Viral Core Proteins | 1 | 2009 | 8 | 0.320 |
Why?
|
| Proteolysis | 2 | 2021 | 55 | 0.320 |
Why?
|
| Pyridines | 2 | 2006 | 102 | 0.310 |
Why?
|
| Virus Replication | 1 | 2008 | 62 | 0.300 |
Why?
|
| Protein Binding | 4 | 2021 | 636 | 0.290 |
Why?
|
| Kinetics | 4 | 2021 | 538 | 0.280 |
Why?
|
| Mutation | 2 | 2021 | 823 | 0.280 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2018 | 35 | 0.240 |
Why?
|
| Enzyme Activation | 2 | 2016 | 265 | 0.230 |
Why?
|
| Molecular Structure | 3 | 2015 | 240 | 0.210 |
Why?
|
| Protein Interaction Maps | 1 | 2021 | 11 | 0.190 |
Why?
|
| Archaeal Proteins | 1 | 2021 | 10 | 0.190 |
Why?
|
| Pseudomonas Infections | 1 | 2021 | 24 | 0.190 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 62 | 0.190 |
Why?
|
| Escherichia coli Infections | 1 | 2021 | 45 | 0.190 |
Why?
|
| Archaea | 1 | 2021 | 50 | 0.180 |
Why?
|
| Ribonucleases | 1 | 2021 | 9 | 0.180 |
Why?
|
| Deoxyribonucleases | 1 | 2021 | 6 | 0.180 |
Why?
|
| Ribosomes | 1 | 2021 | 31 | 0.180 |
Why?
|
| Haemophilus influenzae | 1 | 2021 | 66 | 0.180 |
Why?
|
| RNA | 1 | 2021 | 106 | 0.170 |
Why?
|
| Genome, Bacterial | 1 | 2020 | 68 | 0.170 |
Why?
|
| Mutagens | 1 | 2019 | 6 | 0.160 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2012 | 58 | 0.160 |
Why?
|
| Protein Structure, Secondary | 2 | 2010 | 130 | 0.160 |
Why?
|
| Protein Structure, Tertiary | 3 | 2010 | 283 | 0.160 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2020 | 152 | 0.160 |
Why?
|
| DNA | 1 | 2021 | 365 | 0.160 |
Why?
|
| Nucleic Acid Conformation | 1 | 2019 | 90 | 0.160 |
Why?
|
| Substrate Specificity | 2 | 2021 | 150 | 0.160 |
Why?
|
| Quinolones | 1 | 2018 | 23 | 0.150 |
Why?
|
| Protein Conformation | 4 | 2021 | 253 | 0.150 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 302 | 0.150 |
Why?
|
| Sequence Alignment | 2 | 2014 | 111 | 0.130 |
Why?
|
| Host-Pathogen Interactions | 1 | 2016 | 89 | 0.130 |
Why?
|
| Palladium | 1 | 2015 | 9 | 0.120 |
Why?
|
| Humans | 8 | 2022 | 27175 | 0.120 |
Why?
|
| Time Factors | 1 | 2019 | 1573 | 0.120 |
Why?
|
| Anthrax | 2 | 2012 | 85 | 0.120 |
Why?
|
| Staphylococcus | 1 | 2014 | 18 | 0.110 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 679 | 0.110 |
Why?
|
| Leucovorin | 1 | 2014 | 16 | 0.110 |
Why?
|
| NADP | 1 | 2014 | 38 | 0.110 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 1041 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 591 | 0.100 |
Why?
|
| Bioterrorism | 1 | 2012 | 28 | 0.100 |
Why?
|
| Microarray Analysis | 1 | 2012 | 59 | 0.100 |
Why?
|
| High-Throughput Screening Assays | 1 | 2012 | 36 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2012 | 120 | 0.100 |
Why?
|
| Dimerization | 2 | 2009 | 76 | 0.090 |
Why?
|
| Protein Structure, Quaternary | 2 | 2006 | 26 | 0.080 |
Why?
|
| X-Ray Diffraction | 1 | 2009 | 41 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2009 | 25 | 0.080 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 1 | 2009 | 44 | 0.080 |
Why?
|
| Thermodynamics | 1 | 2008 | 86 | 0.070 |
Why?
|
| Cryoglobulins | 1 | 2006 | 2 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2006 | 28 | 0.070 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2006 | 20 | 0.070 |
Why?
|
| Bence Jones Protein | 1 | 2003 | 1 | 0.050 |
Why?
|
| Weightlessness | 1 | 2003 | 5 | 0.050 |
Why?
|
| Space Flight | 1 | 2003 | 17 | 0.050 |
Why?
|
| Animals | 1 | 2016 | 10082 | 0.050 |
Why?
|
| Genome, Archaeal | 1 | 2021 | 9 | 0.050 |
Why?
|
| Gene Expression Regulation, Archaeal | 1 | 2021 | 6 | 0.050 |
Why?
|
| Referral and Consultation | 1 | 2022 | 94 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2021 | 93 | 0.050 |
Why?
|
| Catalysis | 2 | 2015 | 133 | 0.050 |
Why?
|
| Qualitative Research | 1 | 2022 | 175 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2021 | 147 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2014 | 66 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 102 | 0.030 |
Why?
|
| Water | 2 | 2006 | 131 | 0.030 |
Why?
|
| Francisella tularensis | 1 | 2012 | 1 | 0.030 |
Why?
|
| National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2012 | 2 | 0.030 |
Why?
|
| Brucella abortus | 1 | 2012 | 3 | 0.030 |
Why?
|
| Yersinia pestis | 1 | 2012 | 3 | 0.030 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2012 | 9 | 0.030 |
Why?
|
| Stereoisomerism | 1 | 2012 | 45 | 0.020 |
Why?
|
| Drug Discovery | 1 | 2012 | 32 | 0.020 |
Why?
|
| Staphylococcal Infections | 1 | 2012 | 81 | 0.020 |
Why?
|
| Fluorescence | 1 | 2007 | 47 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2007 | 241 | 0.020 |
Why?
|
| Structural Homology, Protein | 1 | 2006 | 8 | 0.020 |
Why?
|
| Gels | 1 | 2006 | 26 | 0.020 |
Why?
|
| United States | 1 | 2012 | 2063 | 0.020 |
Why?
|
| Glycosylation | 1 | 2006 | 69 | 0.020 |
Why?
|
| Cold Temperature | 1 | 2006 | 34 | 0.020 |
Why?
|
| Lysine | 1 | 2006 | 71 | 0.020 |
Why?
|
| Allosteric Regulation | 1 | 2005 | 18 | 0.020 |
Why?
|
| Models, Biological | 1 | 2007 | 448 | 0.010 |
Why?
|
| Neutron Diffraction | 1 | 2003 | 2 | 0.010 |
Why?
|
| Crystallization | 1 | 2003 | 49 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2003 | 29 | 0.010 |
Why?
|